EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Belite Bio's enterprise value is $1,357.76 Mil.
Belite Bio's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil. Therefore, Belite Bio's EV-to-Revenue for today is .
The historical rank and industry rank for Belite Bio's EV-to-Revenue or its related term are showing as below:
BLTE's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.73 * Ranked among companies with meaningful EV-to-Revenue only.
As of today (2024-06-24), Belite Bio's stock price is $48.50.
Belite Bio's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00. Therefore, Belite Bio's PS Ratio for today is .
Belite Bio EV-to-Revenue Historical Data
The historical data trend for Belite Bio's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Belite Bio's EV-to-Revenue
For the Biotechnology subindustry, Belite Bio's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Belite Bio's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Belite Bio's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Belite Bio's EV-to-Revenue falls into.
Belite Bio's current Enterprise Value is $1,357.76 Mil.
Belite Bio's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Belite Bio's share price for today is $48.50.
Belite Bio's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Belite Bio EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Belite Bio's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BLTE has been successfully added to your 